Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Gilead 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Gilead 3Q

Antiviral product sales up 13%

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Gilead

3Q Revenues: $2.4 billion (+14%)

3Q Earnings: $675.5 million (-9%)

YTD Revenues: $7.1 billion (+15%)

YTD Earnings: $1.8 billion (-14%)

Comments: Antiviral product sales increased 13% to $2.0 billion. Atripla sales increased 9% to $865.4 million. Sales of Truvada increased 8% to $804.2 million. Sales of Viread increased 11% to $214.9 million. Sales of Complera/Eviplera grew more than fivefold to $99.3 million. Sales of Stribild, which launched in the U.S. in August 2012, were $17.5 million. Cardiopulmonary product sales increased 24% to $200.1 million. Other product sales were $122.0 million, up 11%. Royalty, contract and other revenues were $68.6 million in the quarter, up 23%. R&D expenses were $465.8 million compared to $290.1 million in 3Q11.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters